D. Díaz-García

Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.

R. Rosell, A. Cardona, L. Raez, 2021, Lung cancer.

Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.

A. Cardona, O. Arrieta, Camilo Molina-Romero, 2021, Cancer biomarkers : section A of Disease markers.

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort

A. Cardona, J. Saam, O. Arrieta, 2021, Oncology.

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer

A. Cardona, A. Avilés-Salas, O. Arrieta, 2022, Current oncology.

Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.

O. Arrieta, Z. Zatarain-Barrón, R. Gerson, 2020, Lung cancer.

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.

R. Rosell, A. Cardona, O. Arrieta, 2020, JAMA oncology.